SciELO - Scientific Electronic Library Online

SciELO - Scientific Electronic Library Online

Referencias del artículo

FIGUEROA CASAS, Juan Carlos  y  ASOCIACION ARGENTINA DE MEDICINA RESPIRATORIA. Grupo Recomendaciones de EPOC et al. Recomendaciones para la prevención, diagnóstico y tratamiento de LA EPOC en la Argentina. Medicina (B. Aires) [online]. 2012, vol.72, n.4, suppl.1, pp. 1-33. ISSN 0025-7680.

    1. Figueroa Casas JC, Abbate E, Martelli N, et al. Enfermedad pulmonar obstructiva crónica. Consenso Argentino. Medicina (B Aires) 1994; 54: 671-96. [ Links ]

    2. Gene R, Giugno E, Abbate E, et al. Nuevo Consenso Argentino de EPOC. Medicina (B Aires) 2003; 63: 419-46. [ Links ]

    3. Guyatt G, Gutterman D, Baumann MH, et al. Grading strength of recommendations and quality of evidence in clinical guidelines: Report from an American College of Chest Physicians task force. Chest 2006; 129: 174-81. [ Links ]

    4. Global Strategy for Diagnosis, Management, and Prevention of COPD (GOLD Guidelines) Updated 2010. En: http://goldcopd.com/GuidelinesResources, consultado el 28 de septiembre 2011. [ Links ]

    5. Celli BR, MacNee W, and committee members. ATS/ ERS TASK FORCE. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004; 23: 932-46. [ Links ]

    6. Russi EW, Leuenberger P, Brändli O, et al. Management of chronic obstructive pulmonary disease: the Swiss guidelines. Swiss Med Wkly 2002; 132: 67-78. [ Links ]

    7. McKenzie DK, Frith PA, Burdon JGW, Town GI. The COPDX Plan: Australian and New Zealand Guidelines for the management of Chronic Obstructive Pulmonary Disease 2003. MJA 2003; 178: S1-S40. [ Links ]

    8. Pellegrino R, Viegi G, Brusasco V, et al. Interpretative strategies for lung function tests. Eur Respir J 2005; 26: 948-68. [ Links ]

    9. Anthonisen NR, Connett JE, Murray RP. Smoking and lung function of Lung Health Study participants after 11 years. Am J Respir Crit Care Med 2002; 166: 675-9. [ Links ]

    10. Fletcher C, Peto R. The natural history of chronic airflow obstruction. BMJ 1977; 1: 1645-8. [ Links ]

    11. Burrows B, Knudson RJ, Cline MG, Lebowitz MD. Quantitative relationships between cigarette smoking and ventilatory function. Am Rev Respir Dis 1977; 115:195-205. [ Links ]

    12. Doll R, Peto R, Boreham J, Sutherland I. Mortality in relation to smoking: 50 years' observations on male British doctors. BMJ 2004; 328: 1519-27. [ Links ]

    13. Kohansal R, Martínez C, Agustí A, Buist AS, Mannino DV, Soriano JB. The natural history of chronic airflow obstruction revisited. An analysis of the Framingham offspring cohort. Am Rev Respir Crit Care Med 2009; 180:3-10. [ Links ]

    14. Løkke A, Lange P, Scharling H, et al. Developing COPD: a 25 year follow up study of the general population. Thorax 2006; 61: 935- 9. [ Links ]

    15. Hersh CP, DeMeo DL, Al-Ansari E, et al. Predictors of survival in severe, early onset COPD. Chest 2004; 126: 1443-51. [ Links ]

    16. Balmes J, Becklake M, Blanc P, et al. American Thoracic Society statement: occupational contribution to the burden of airway disease. Am J Respir Crit Care Med 2003; 167: 787-97. [ Links ]

    17. Trupin L, Earnest G, San Pedro M, et al. The occupational burden of chronic obstructive pulmonary disease. Eur Respir J 2003; 22: 462-9. [ Links ]

    18. Harber P, Tashkin D, Simmons M, et al. Effect of Occupational Exposures on Decline of Lung Function in Early Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 2007; 176: 994-1000. [ Links ]

    19. Hu G, Zhou Y, Tian J, et al. Risk of COPD from exposure to biomass smoke: a metaanalysis. Chest 2010; 138: 20-31. [ Links ]

    20. Pelkonen M, Notkola I-L, Nisssinen A, et al. Thirty-year cumulative incidence of chronic bronchitis and COPD and chronic bronchitis in relation to 30-year pulmonary function and 40-year mortality: a follow-up in middle-aged rural men. Chest 2006; 130: 1129-37. [ Links ]

    21. Lundback B, Lindberg A, Lindstrom M, et al. Not 15 but 50% of smokers develop COPD? Report from the Obstructive Lung Disease in Northern Sweden Studies. Respir Med 2003; 97: 115-22. [ Links ]

    22. Curtis JL, Freeman CM, Hogg JC. The Immunopathogenesis of Chronic Obstructive Pulmonary Disease: Insights from Recent Research. Proc Am Thorac Soc 2007; 4: 512-21. [ Links ]

    23. Cosio MG, Majo J, Cosio MG. Inflammation of the airways and lung parenchyma in COPD: role of T cells. Chest 2002; 121: 160S-5S. [ Links ]

    24. Lungarella G, Cavarra E, Lucatelli M, Martorana PA. The dual role of neutrophil elastase in lung destruction and repair. Internat J Biochem & Cell Biol 2008; 40: 1287-96. [ Links ]

    25. Demedts IK, Bracke KR, Van Pottelberge G, et al. Accumulation of dendritic cells and increased CCL20 levels in the airways of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 175: 998-1005. [ Links ]

    26. Vijayanand P, Seumois G, Pickard C, et al. Invariant Natural Killer T Cells in Asthma and Chronic Obstructive Pulmonary Disease. N Engl J Med 2007; 356: 1410-22. [ Links ]

    27. Voelkel N, Taraseviciene-Stewart L. Emphysema: an autoimmune disease? Proc Am Thorac Soc 2005; 2: 23-5. [ Links ]

    28. Chung KF. Cytokines in chronic obstructive pulmonary disease. Eur Respir J 2001; 34: 50S-9S. [ Links ]

    29. Di Stefano A, Capelli A, Lusuardi M, et al. Severity of airflow limitation is associated with severity of airway inflammation in smokers. Am J Respir Crit Care Med 1998; 158: 1277-85. [ Links ]

    30. Rabe KF, Beghe B, Luppi F, Fabbri LM. Update in Chronic Obstructive Pulmonary Disease 2006. Am J Respir Crit Care Med 2007; 175: 1222-32. [ Links ]

    31. MacNee W. Pathogenesis of Chronic Obstructive Pulmonary Disease. Clin Chest Med 2007; 28: 479-513. [ Links ]

    32. Hogg JC, Macklem PT, Thurlbeck WM. Site and nature of airway obstruction in chronic obstructive lung disease. N Engl J Med 1968; 278: 1355-60. [ Links ]

    33. Hogg JC, Chu F, Utokaparch S, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004; 350: 2645-53. [ Links ]

    34. Saetta M, Turato G, Maestrelli P, et al. Cellular and structural bases of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 163: 1304-9. [ Links ]

    35. Grumelli S, Corry DB, Song LZ, et al. An immune basis for lung parenchymal destruction in chronic obstructive pulmonary disease and emphysema. PLoS Med 2004; 1: 75-83. [ Links ]

    36. Gross NJ, Co E, Skorodin MS. Cholinergic bronchomotor tone in COPD. Estimates of its amount in comparison with that in normal smokers. Chest 1989; 96: 984-7. [ Links ]

    37. Tracey KJ. Physiology and immunology of the cholinergic anti-inflammatory pathway. J Clin Invest 2007; 117: 289-96. [ Links ]

    38. Willemse BW, ten Hacken NH, Rutgers B, Lesman-Leegte IG, Postma DS, Timnes W. Effect of 1-year smoking cessation on airway inflammation in COPD and asymptomatic smokers. Eur Respir J 2005; 26: 835-45. [ Links ]

    39. Willemse BW, Postma DS, Timens W, et al. The impact of smoking cessation on respiratory symptoms, lung function, airway hyperresponsiveness and inflammation. Eur Respir J 2004; 23: 464-76. [ Links ]

    40. Cosio M, Ghezzo H, Hogg JC, et al. The relations between structural changes in small airways and pulmonary-function tests. N Engl J Med 1978; 298: 1277-81. [ Links ]

    41. Jeffery PK. Comparison of the structural and inflammatory features of COPD and asthma. Giles F. Filley Lecture. Chest 2000; 117: 251S-60S. [ Links ]

    42. O'Donnell DE, Revill SM, Webb KA. Dynamic hyperinflation and exercise intolerance in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164: 770-7. [ Links ]

    43. Peinado VI, Barbera JA, Abate P, et al. Inflammatory reaction in pulmonary muscular arteries of patients with mild chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 159: 1605-11. [ Links ]

    44. Hardie JA, Buist AS, Vollmer WM, et al. Risk of over-diagnosis of COPD in asymptomatic elderly never-smokers. Eur Respir J 2002; 20: 1117-22. [ Links ]

    45. Celli BR, Halbert RJ, Isonaka S, Schau B. Population impact of different definitions of airway obstruction. Eur Respir J 2003; 22: 268-73. [ Links ]

    46. Shirtcliffe P, Weatherhall M, Marsh S, et al. COPD prevalence in a random population survey: a matter of definition. Eur Resp J 2007; 30: 232-9. [ Links ]

    47. Cerveri I, Corsico AG, Accordini S, et al. Underestimation of airflow obstruction among young adults using FEV1/FVC<70% as a fixed cut-off: a longitudinal evaluation of clinical and functional outcomes. Thorax 2008; 63: 1040-5. [ Links ]

    48. Pellegrino R, Brusasco V, Viegi G, et al. Definition of COPD: Based on evidence or opinion? Eur Resp J 2008; 31: 681-90. [ Links ]

    49. Vollmer W, Gislason P, Burney P, et al. Comparison of spirometry criteria for the diagnosis of COPD: results from the BOLD study. Eur Resp J 2009; 34: 588-97. [ Links ]

    50. Quanjer PH. En: http://www.spirxpert.com/controversies/controversy.html , consultado el 02/01/2011. [ Links ]

    51. Pérez-Padilla R, Torre Bouscoulet L, Vázquez-García JC, et al. Valores de referencia para la espirometría después de la inhalación de 200 ug de salbutamol. Arch Bronconeumol 2007; 43: 530-4. [ Links ]

    52. Celli BR, Cote CG, Marin JM, et al. The body mass index, airflow obstruction, dyspnea, and exercise capacity index in Chronic Obstructive Pulmonary Disease. N Eng J Med 2004; 350: 1005-12. [ Links ]

    53. Vestbo J, Anderson W, Coxson HO, et al. Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE). Eur Respir J 2008; 31: 869-73. [ Links ]

    54. Punturieri A, Croxton T, Weinmann G,Kiley J. Chronic Obstructive Pulmonary Disease: a view from the NHLBI. Am J Respir Crit Care Med 2008; 178: 441-3. [ Links ]

    55. Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Eng J Med 2010; 363: 1128-38. [ Links ]

    56. Murray CJL, Lopez AD. Evidence-based health policy- lessons from the Global Burden of Disease Study. Science 1996; 274: 740-3. [ Links ]

    57. Murray CJL, Lopez AD, eds. The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries and risk factors in 1990 and projected to 2020. Cambridge, MA: Harvard University Press; 1996. [ Links ]

    58. Lopez AD, Mathers CD, Ezzati M, et al. Global burden of disease and risk factors. Washington, DC: The World Bank, 2006. [ Links ]

    59. Tirimanna PR, van Schayck P, den Otter JJ, et al. Prevalence of asthma and COPD in general practice in 1992: Has it changed since 1977? Br J Gen Pract 1996; 46: 277-8. [ Links ]

    60. Halbert RJ, Natoli JL, Gano A, et al. Global burden of COPD: systematic review and meta-analysis. Eur Respir J 2006; 528: 523-32. [ Links ]

    61. Halbert RJ, Isonaka S, George D, et al. Interpreting COPD prevalence estimates: what is the true burden of disease? Chest 2003; 123: 1684-92. [ Links ]

    62. Menezes AMB, Perez-Padilla R, Jardim JB, et al. Chronic obstructive pulmonary disease in five Latin American cities (the PLATINO study): a prevalence study. Lancet 2005; 366: 1875-81. [ Links ]

    63. Buist AS, McBurnie MA, Vollmer WM, et al. International variation in the prevalence of COPD (the BOLD study): a population-based prevalence study. Lancet 2007; 370: 741-50. [ Links ]

    64. Caballero A, Torres-Duque CA, Jaramillo C, et al. Prevalence of chronic obstructive pulmonary disease in five Columbian cities situated at low, medium and high altitude (PREPOCOL study). Chest 2008; 133: 343-9. [ Links ]

    65. Gomez RM, Zabert GE, Jossen RA, Croce JD, and Adult Wheezing Study Group. Adult wheezing prevalence in Argentina: Preliminary Report ATS 2007. [ Links ]

    66. Sívori M, Sáenz C, Riva Posse C. Mortalidad por Asma y Enfermedad Pulmonar Obstructiva Crónica en Argentina (1980-1998). Medicina B Aires 2001; 61: 513-21. [ Links ]

    67. National Institute for Health and Clinical Excellence-Measuring effectiveness and cost effectiveness: the QALY. En: http://www.nice.org.uk/newsroom/features/measuringeffectivenessandcosteffectivenesstheqaly.jsp , consultado el 10/12/10. [ Links ]

    68. WHO. The Global Burden of disease concept. En: http://www.who.int/quantifying_ehimpacts/publications/en/9241546204chap3.pdf , consultado el 14/12/2010. [ Links ]

    69. Qaseem A, Snow V, Shekelle P, et al. Diagnosis and Management of Stable Chronic Obstructive Pulmonary Disease: A Clinical Practice Guideline from American College of Physicians. Ann Intern Med 2007; 147: 633-8. [ Links ]

    70. National Institute for Clinical Excellence (NICE). National clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care Thorax 2004; 59 (Suppl I): 1-232. [ Links ]

    71. Gan WQ, Man SF, Senthiselvan A, Sin DD. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax 2004; 59: 574-80. [ Links ]

    72. Peces-Barba G, Barberà JA, Agustí A, et al. Guía clínica SEPAR-ALAT de diagnóstico y tratamiento de la Enfermedad Pulmonar Obstructiva Crónica. Arch Bronconeumol 2008; 44: 271-81. [ Links ]

    73. Rhodius E., Caneva J., Sivori M. Consenso Argentino de Oxigenoterapia Domiciliaria. Medicina (B Aires) 1998; 58: 85-94. [ Links ]

    74. Barker A., Brantlyu M., Campbell E., et al. Alpha 1 antitrypsin deficiency: Memorandum from a WHO meeting. Bulletin WHO 1997; 75: 397-415. [ Links ]

    75. ATS/ERS Statement: Standards for the diagnosis and management of individuals with alpha 1 antitrypsin deficiency. Am J Respir Crit Care Med 2003; 168: 820-2. [ Links ]

    76. Stockley RA, Bayley D, Hill SL, et al Assessment of airway neutrophils by sputum colour: correlation with airways inflammation. Thorax 2001; 56: 366-72. [ Links ]

    77. Klein JS, Gamsu G, Webb WR, et al. High-resolution CT diagnosis of emphysema in symptomatic patients with normal chest radiograph and isolated low diffusing capacity. Radiology 1992; 182: 817-21. [ Links ]

    78. Arakawa H, Webb WR. Air trapping on expiratory high - resolution CT scans in the absence of inspiratory scan abnormalities: correlation with pulmonary function tests and differential diagnosis. Am J Roentgenol 1998; 170: 1349-53. [ Links ]

    79. Muller NL, Coxson H. Imaging the lung in patients with chronic obstructive pulmonary disease. Thorax 2002; 57: 982-5. [ Links ]

    80. Fishman A., Martinez F, Naunheim K et al. A Randomized Trial Comparing Lung-Volume Reduction Surgery with Medical Therapy for Severe Emphysema. New Engl J Med 2003; 348: 2059-73. [ Links ]

    81. Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J 2005; 26: 319-38. [ Links ]

    82. Anthonisen NR, Wright EC, Hodgkin JE. Prognosis in chronic obstructive pulmonary disease. Am Rev Respir Dis 1986; 133: 14-20. [ Links ]

    83. Burrows B. The course and prognosis of different types of chronic airflow limitation in a general population sample from Arizona: comparison with the Chicago "COPD" series. Am Rev Respir Dis 1989; 140: S92-S94. [ Links ]

    84. Nolan D, White P, Pearson MG. FEV1 and PEF in COPD management. Thorax 1999; 54: 468-9. [ Links ]

    85. Hughes J, Pride N. In defence of the carbón monoxide transfer coefficient KCO (TL/VA). Eur Respir J 2001; 17: 168-74. [ Links ]

    86. Bolliger CT, Perruchoud AP. Functional evaluation of the lung resection candidate. Eur Respir J 1998;1: 198-212. [ Links ]

    87. Wanger J, Clausen JL, Coates A, et al. Standardisation of the measurement of lung volumes. Eur Respir J 2005; 26: 511-22. [ Links ]

    88. Casanova C, Cote C, de Torres JP, et al. Inspiratory-tototal lung capacity ratio predicts mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005; 171: 591-7. [ Links ]

    89. Colice GL, Shafazand S, Griffin JP, et al. Physiologic Evaluation of the Patient With Lung Cancer Being Considered for Resectional Surgery. ACCP Evidenced-Based Clinical Practice Guidelines (2nd Ed.) Chest 2007; 132: S161-S177. [ Links ]

    90. Celli BR. Clinical and Physiologic Evaluation of Respiratory Muscle Function. Clin Chest Med 1989; 10: 199-21. [ Links ]

    91. Butland R, Pang J, Gross E, et al. Two, six and twelve minutes walking-tests in respiratory disease. Br Med J 1982; 284: 1607-8. [ Links ]

    92. Ambrosino N. Field tests in pulmonary diseases. Thorax 1999; 54: 191-3. [ Links ]

    93. Sívori M, Sáenz C. Prueba de caminata de carga progresiva (Shuttle test) en enfermedad pulmonar obstructiva grave. Medicina (B Aires) 2010; 70: 305-10. [ Links ]

    94. Sin DD, Anthonisen NR, Soriano JB, Agusti AG. Mortality in COPD: role of comorbidities. Eur Respir J 2006; 28: 1245-57. [ Links ]

    95. Decramer M, Rennard S, Troosters T, et al. COPD as a lung disease with systemic consequences-clinical impact, mechanisms, and potential for early intervention. J COPD 2008; 5: 235-56. [ Links ]

    96. Agustí A. Systemic effects of chronic obstructive pulmonary disease: what we know and what we don't know (but should). Proc Am Thorac Soc 2007; 4: 522-5. [ Links ]

    97. Agusti A, Soriano JB. COPD as a systemic disease. J COPD 2008; 5: 133-8. [ Links ]

    98. Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD. Eur Respir J 2009; 33: 1165-85. [ Links ]

    99. American Thoracic Society European Respiratory Society. Skeletal muscle dysfunction in chronic obstructive pulmonary disease. Am J Resp Crit Care Med 1999; 159: 2S-40. [ Links ]

    100. Anthonisen NR, Conte JE, Enright PL, Manfreda J. Hospitalizations and mortality in the Lung Health Study. Am J Resp Crit Care Med 2002; 166: 333-9. [ Links ]

    101. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary idease. N Engl J.Med 2007; 356: 775-89. [ Links ]

    102. Maclay JD, McAllister A, Mac Nee W. Cardiovascular risk in chronic obstructive pulmonary disease. Respirology 2007; 12: 634-41. [ Links ]

    103. Iwamoto H, Yokoyama A, Kitahara Y, et al. Airflow limitation in smokers is associated with subclinical atherosclerosis. Am J Respir Crit Care Med 2009; 179: 35-40. [ Links ]

    104. Maclay JD, McAllister DA, Mills NL, et al. Vascular dysfunction in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009; 180: 513-20. [ Links ]

    105. Similowski T, Agusti A, MacNee W, Schonhofer B. The potential impact of anaemia of chronic disease in COPD. Eur Respir J 2006; 27: 390-6. [ Links ]

    106. Cote C, Zilberberg MD, Mody SH, et al. Haemoglobin level and its clinical impact in a cohort of patients with COPD. Eur Respir J 2007; 29: 923-9. [ Links ]

    107. Antonelli Incalzi R, Corsonello A, Pedone C, et al. Depression and drug utilization in an elderly population. Ther Clin Risk Manag 2005; 1: 55-60. [ Links ]

    108. Chatila WM, Thomashow BM, Minai OA, et al. Comorbidities in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2008; 5: 549-55. [ Links ]

    109. Sin DD, Man JP, Man SF. The risk of osteoporosis in Caucasian men and women with obstructive airway disease. Am J Med 2003; 114: 10-4. [ Links ]

    110. Bolton CE, Ionescu AA, Shiels KM, et al. Associated loss of fat-free mass and bone mineral density in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004; 170: 1286-93. [ Links ]

    111. Rana JS, Mittleman MA, Sheikh J, et al Chronic obstructive pulmonary disease, asthma, and risk of diabetes type 2 in women. Diabetes Care 2004; 27: 2478-84. [ Links ]

    112. Laghi F, Adiguzel N, Tobin MJ. Endocrinological derangements in COPD. Eur Respir J 2009; 34: 975-96. [ Links ]

    113. Cosio MG, Saetta M, Agusti A. Immunologic Aspects of Chronic Obstructive Pulmonary Disease. N Engl J Med 2009; 360: 2445-54. [ Links ]

    114. Wasswa Quintu-Kintu S, Gan WQ, Man SF, et al. Relationship between reduced forced expiratory volume in one second and the risk of lung cancer: a systematic review and metanalysis. Thorax 2005; 60: 570-5. [ Links ]

    115. Casanova C, de Torres JP, Navarro J, et al. Microalbuminuria and hypoxemia in patients with chronic obstructive pulmonary disease. Am J Resp Crit Care Med 2010; 182: 1004-10. [ Links ]

    116. Kinsman RA, Yaroush RA, Fernandez E, Dirks JF, Schocket M, Fukuhara J. Symptoms and experiences in chronic ronchitis and emphysema. Chest 1983; 83: 755-76. [ Links ]

    117. Tirlapur VG, Mir MA. Nocturnal hypoxemia and associated electrocardiographic changes in patients with chronic obstructive airways disease. N Engl J Med 1982; 306: 125-30. [ Links ]

    118. Fletcher EC, Luckett RA, Miller T, et al. Pulmonary vascular hemodynamics in chronic lung disease patients with and without oxyhemoglobin desaturation during sleep. Chest 1989; 95: 757-64. [ Links ]

    119. McNicholas WT, Fitzgerald MX. Nocturnal death among patients with chronic bronchitis and emphysema. Br Med J (Clin Res Ed) 1984; 289: 878. [ Links ]

    120. Klink M, Quan SF. Prevalence of reported sleep disturbances in a general adult population and their relationship to obstructive airways diseases. Chest 1987; 91: 540-6. [ Links ]

    121. Douglas NJ, Calverley PM, Leggett RJ, et al. Transient hypoxaemia during sleep in chronic bronchitis and emphysema. Lancet 1979; 1: 1-4. [ Links ]

    122. Mulloy E, McNicholas WT. Ventilation and gas exchange during sleep and exercise in severe COPD. Chest 1996; 109: 387-94. [ Links ]

    123. Krachman S, Minai OA, Scharf SM. Sleep abnormalities and treatment in emphysema. Proc Am Thorac Soc 2008; 5: 536-42. [ Links ]

    124. Mulloy E, McNicholas WT. Theophylline improves gas exchange during rest, exercise, and sleep in severe chronic obstructive pulmonary disease. Am Rev Respir Dis 1993; 148: 1030-6. [ Links ]

    125. Martin RJ, Bartelson BL, Smith P, et al. Effect of ipratropium bromide treatment on oxygen saturation and sleep quality in COPD. Chest 1999; 115: 1338-45. [ Links ]

    126. McNicholas WT, Calverley PM, Lee A, Edwards JC. Long-acting inhaled anticholinergic therapy improves sleeping oxygen saturation in COPD. Eur Respir J 2004; 23: 825-31. [ Links ]

    127. Jolly E, Aguirre L, Jorge E, et al. Acute effect of lorazepam on respiratory muscles in stable patients with chronic obstructrive pulmonary disease. Medicina (B Aires) 1996; 54: 472-8. [ Links ]

    128. Hudgel DW, Martin RJ, Capehart M, et al. Contribution of hypoventilation to sleep oxygen desaturation in chronic obstructive pulmonary disease. J Appl Physiol 1983; 55: 669-77. [ Links ]

    129. Becker HF, Piper AJ, Flynn WE, et al. Breathing during sleep in patients with nocturnal desaturation. Am J Respir Crit Care Med 1999; 159: 112-8. [ Links ]

    130. Connaughton JJ, Catterall JR, Elton RA, et al. Do sleep studies contribute to the management of patients with severe chronic obstructive pulmonary disease? Am Rev Respir Dis 1988; 138: 341-4. [ Links ]

    131. Sampol G, Sagales MT, Roca A, et al. Nasal continuous positive airway pressure with supplemental oxygen in coexistent sleep apnoea-hypopnoea syndrome and severe chronic obstructive pulmonary disease. Eur Respir J 1996; 9: 111-6.132. [ Links ]

    132. de Miguel J, Cabello J, Sanchez-Alarcos JM, et al. Long-term effects of treatment with nasal continuous positive airway pressure on lung function in patients with overlap syndrome. Sleep Breath 2002; 6: 3-10. [ Links ]

    133. Sampol G, Sagales MT, Roca A, de la Calzada MD, Bofill JM, Morell F. Nasal continuous positive airway pressure with supplemental oxygen in coexistent sleep apnoea-hypopnoea syndrome and severe chronic obstructive pulmonary disease. Eur Respir J 1996;9: 111-6. [ Links ]

    134. Ibáñez M, Aguilar J, Maderal M, et al. Sexuality in chronic respiratory failure: coincidences and divergentes between patient and primary caregiver. Respir Med 2001; 95: 975-9. [ Links ]

    135. Köseoglu N, Köseoglu H, Ceylan E, et al. Erectile dysfunction prevalence and sexual function status in patients with chronic obstructive pulmonary disease. J Urol 2005; 174: 249-52. [ Links ]

    136. Charam N. Does sildenafil also improve breathing? Chest 2001; 120: 305-6. [ Links ]

    137. Bolliger CT. Evaluation of operability before lung resection. Curr Opin Pulm Med 2003; 9: 321-6. [ Links ]

    138. Brooks-Brunn JA. Predictors of postoperative pulmonary complications following abdominal surgery. Chest 1997; 111: 564-71. [ Links ]

    139. Arozullah AM, Daley J, Henderson WG, Khuri SF. Multifactorial risk index for predicting postoperative respiratory failure in men after major noncardiac surgery. The National Veterans Administration Surgical Quality Improvement Program. Ann Surg. 2000; 232: 242-53. [ Links ]

    140. McAlister FA, Khan NA, Straus SE, Papaioakim M, Fisher BW, Majumdar SR, Gajic O, Daniel M, Tomlinson G. Accuracy of the preoperative assessment in predicting pulmonary risk after nonthoracic surgery. Am J Respir Crit Care Med 2003; 167: 741-4. [ Links ]

    141. Bolton JWR, Weiman DS, Haynes JL, et al. Stair climbing as an indicator of pulmonary function. Chest 1987; 92: 783-7. [ Links ]

    142. Anthonisen NR, Connet JE, Kiley JP, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. JAMA 1994; 272: 1497-505. [ Links ]

    143. Tashkin D, Kamer R, Bailey W, et al. Smoking cessation in patients with chronic obstructive pulmonary disease, double-blind placebo controlled, randomized trial. Lancet 2001; 357: 1571-5. [ Links ]

    144. Scanlon P, Connet J.E, Waller LA, et al. Smoking cessation and lung function in mild-to-moderate Chronic Obstructive Pulmonary Disease. The Lung Health Study. Am J Respir Crit Care Med 2000; 161: 381-90. [ Links ]

    145. Tashkin DP, Celli B, Senn S, et al. UPLIFT Study Investigators. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008; 359: 1543-54. [ Links ]

    146. Jenkins CR, Jones PW, Calverley PM, et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study. Respir Res 2009; 10: 59-65. [ Links ]

    147. Decramer M, Celli B, Kesten S, et al. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet 2009; 374: 1171-8. [ Links ]

    148. Lancaster T, Stead LF. 2006 Physician advice for smoking cessation. Cochrane Database of Systematic Reviews. Cochrane Database Syst Rev 2004;3: CD000146. [ Links ]

    149. Guía nacional de tratamiento de la adicción al tabaco. Buenos Aires: Ministerio de Salud y Ambiente de la Nación, 2005. [ Links ]

    150. Britton J, Knoox A. Helping people to stop smoking the new smoking cessation guideline. Thorax 1999; 54: 1-2. [ Links ]

    151. Fiore, MC, Bailey WC, Cohen SJ, et al. A clinical practice guideline for treating tobacco use and dependence. A US Public Health Service Report. JAMA 2000; 283: 3244-54. [ Links ]

    152. American Medical Association. Guideline for a diagnosis and tratment of nicotine dependence: How to help pacients to stop smoking. Washington D.C: American Medical Association, 1994. [ Links ]

    153. Lancaster T, Stead L, Sigal C, Sowden A. Effectiveness of interventions to help people to stop smoking: findings from the Cochrane Library. BMJ 2000; 321: 355-8. [ Links ]

    154. Silagy C, Lancaster T, Stead L, et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev. 2004;CD000146. [ Links ]

    155. Jorenby DE, Leischow SJ, Nides MA, et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking-cessation. N Engl J Med 1999; 340: 685-91. [ Links ]

    156. Cahill K, Stead L, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev 2007; CD006103. [ Links ]

    157. Jorenby DE, Hays JT, Rigotti N, et al. Efficacy of varenicline, an alpha4 beta2 nicotine acetylcholine receptor partial agonist, vs placebo or sustained release bupropion for smoking cessation randomized controlled trial. JAMA 2006; 296: 53-63. [ Links ]

    158. Nides M, Oncken C, Gonzales D, et al. Smoking cessation with varenicline selective alpha4beta2 nicotinic receptor partial agonist result from 7 week, randomized placebo - and bupropion-controlled trial with 1 year follow up. Arch Inter Med 2006; 166: 1561-8. [ Links ]

    159. Ebbert JO, Croghan IT, Sood A, et al. Varenicline and bupropion sustained-release combination therapy for smoking cessation. Nicotine Tob Res 2009; 11: 234-9. [ Links ]

    160. Shah SD, Wilken LA, Winkler SR, Lin SJ. Systematic review and meta-analysis of combination therapy for smoking cessation. J Am Pharm Assoc 2008; 48: 659-65. [ Links ]

    161. Becoña E. Tratamiento psicológico del tabaquismo. Adicciones 2004; 16: 227-65. [ Links ]

    162. Nerín I, Novella P, Crucelaegui A, et al. Factores predictores de éxito a los 6 meses en fumadores tratados en una unidad de tabaquismo. Arch Bronconeumol 2004; 40: 558-62. [ Links ]

    163. Juneman A, Legarreta G. Inhalación de humo de leña: una causa relevante pero poco reconocida de Enfermedad Pulmonar Obstructiva Crónica. Rev Arg Med Respir 2007; 2: 51-7. [ Links ]

    164. Smith KR, Mehta S, Maeusezahl-feuz. Indoor air pollution from house hold use of solid fuels. In: Ezzati M.; López A.D.; Rodgers A.; Murray C.J.L. Comparative quantification of health risks. Global and regional burden of disease atribuible to selected mayor risk factors. Geneva: WHO. 2004; 2: 1435-93. [ Links ]

    165. Ko FW, Tam W, Wong TW, et al. Temporal relationship between air pollutants and hospital admissions for chronic obstructive pulmonary disease in Hong Kong. Thorax 2007; 62: 780-5. [ Links ]

    166. Liu S, Zhou Y, Wang X, et al. Biomass fuels are the probable risk factor for chronic obstructive pulmonary disease in rural South China. Thorax 2007; 62: 889-97. [ Links ]

    167. Vestbo J, Sorensen T, Lange P, et al. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controled trial. Lancet 1999; 353: 1819-23. [ Links ]

    168. Altose MD, Redline S, Deitz CD, Quinlan KJ. The Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med 2000; 343: 1902-9. [ Links ]

    169. Highland KB, Strange C, Heffner JE. Long-term effects of inhaled corticosteroids on FEV1 in patients with chronic obstructive pulmonary disease. A meta-analysis. Ann Intern Med 2003; 138: 969-73. [ Links ]

    170. Soriano JB, Sin DD, Zhang X, et al. A pooled analysis of FEV1 decline in COPD patients randomized to inhaled corticosteroids or placebo. Chest 2007; 131: 682-9. [ Links ]

    171. Sutherland ER, Allmers H, Ayas N, et al. Inhaled corticosteroids reduce the progression of airflow limitation in chronic obstructive pulmonary disease: a meta-analysis. Thorax 2003; 58: 937-41. [ Links ]

    172. Celli B.Update on Management of COPD. Chest 2008; 133;1451-62. [ Links ]

    173. Albert P, Calverley P.M.A. Drugs (including oxygen) in severe COPD. Eur Respir J 2008; 31: 1114-24. [ Links ]

    174. Vathenen AS, Britton JR, Ebden P, et al. High-dose inhaled albuterol in severe chronic airflow limitation. Am Rev Respir Dis 1988; 138: 850-5. [ Links ]

    175. Gross NJ, Petty TL, Friedman M, et al. Dose response to ipratropium as a nebulized solution in patients with chronic obstructive pulmonary disease. A three -center study. Am Rev Respir Dis 1989; 139: 1188-91. [ Links ]

    176. Jones PW, Bosh TK. Quality of life changes in COPD patients treated with salmeterol. Am J Respir Crit Care Med 1997; 155: 1283-9. [ Links ]

    177. Man WD, Mustfa N, Nikoletou D, et al. Effect of salmeterol on respiratory muscle activity during exercise in poorly reversible COPD. Thorax 2004; 59: 471-6. [ Links ]

    178. Cazzola M, Matera MG, Santangelo G, et al. Salmeterol and formoterol in partially reversible severe chronic obstructive pulmonary disease: a dose response study. Respir Med 1995; 89: 357-62. [ Links ]

    179. Boyd G, Morice AH, Pounsford JC, et al. An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD). Eur Respir J 1997; 10: 815-21. [ Links ]

    180. Mahler DA, Donohue JF, Barbee RA, et al. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest 1999; 115: 957-65. [ Links ]

    181. Albers R, Ayres J, Backer V, et al. Formoterol in patients with chronic obstructive pulmonary disease: a randomized, controlled, 3-month trial. Eur Respir J 2002; 19: 936-43. [ Links ]

    182. Dahl R, Chung KF, Buhl R, et al. Efficacy of a new once-daily long-acting inhaled 2-agonist indacaterol vs twice-daily formoterol in COPD. Thorax 2010; 65: 473-9. [ Links ]

    183. Stam J, Souren M, Zweers P. The onset of action of formoterol, a new beta-2 adrenoceptor agonist. Int J Clin Pharmacol Ther Toxicol 1993; 31: 23-6. [ Links ]

    184. Rodrigo G., Nannini LJ., Rodríguez-Roisin R. Safety of long-acting -agonists in stable COPD. Chest 2008; 133: 1079-87. [ Links ]

    185. Wang J, Nie B, Xiong W,Xu Y. Effect of long-acting agonist on the frecuency of COPD exacerbation: a metanalysis. J Clin Pharm Ther 2011; Jul 11 (Epub ahead of print). [ Links ]

    186. Rau J. Practical Problems with aerosol therapy in COPD. Respir Care 2006; 51: 158-72. [ Links ]

    187. Berry R, Shinto R, Wong F, et al. Nebulizer vs spacer for bronchodilator delivery. Chest 1989; 96: 1241-6. [ Links ]

    188. Dolovich MB, Ahrens RC, Hess DR, et al. Device selectionand outcomes of aerosol therapy: evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology. Chest 2005; 127: 335-71. [ Links ]

    189. NAEP. National Asthma Education Program. Teach your patients about asthma. A clinician's guide. National Institutes of Health, Bethesda, 1992, Pub. # 92-2737. [ Links ]

    190. Disse B, Speck GA, Rominger KL, et al. Tiotropium (Spiriva): mechanistical considerations and clinical profile in obstructive lung disease. Life Sci 1999; 64: 457-64. [ Links ]

    191. Vincken W, van Noord JA, Greefhorst AP, et al. Improved health outcomes in patients with COPD during 1 year treatment with tiotropium. Eur Respir J 2002; 19: 209-16. [ Links ]

    192. Casaburi R, Mahler DA, Jones PW, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002; 19: 217-24. [ Links ]

    193. O`Donnell DE, Flüge T, Gerken F, et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J 2004; 23: 825-31. [ Links ]

    194. Celli B, Decramer M, Kesten S, et al. Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009; 180: 948-55. [ Links ]

    195. Casaburi R, Kukafka D, Cooper CB, et al. Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD. Chest 2005; 127: 809-17. [ Links ]

    196. Dusser D, Bravo ML, Iacono P. The effect of tiotropium on exacerbations and airflow in patients with COPD. Eur Respir J 2006; 27: 547-55. [ Links ]

    197. Brusasco V, Hodder R, Miravitlles M, et al. Health outcomes following treatment for six month with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax 2003; 58: 399-404. [ Links ]

    198. Niewoehner D, Rice K, Cote C, et al. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator. Ann Intern Med 2005; 143: 317-26. [ Links ]

    199. Vogelmeier C, Hederer B, Glaab B, et al .Tiotropium versus salmeterol for the Prevention of Exacerbations of COPD. N Engl J Med 2011; 354: 1093-103. [ Links ]

    200. Ram FS, Jones PW, Castro AA, et al. Oral theophylline for chronic obstructive pulmonary disease (Cochrane Review). Cochrane Database Syst Rev 2002; 4: CD003902. [ Links ]

    201. Zhou Y, Wang X, Zeng X, et al. Positive benefits of theophylline in a randomized, double-blind, parallel-group, placebo-controlled study of low-dose, slow-release theophylline in the treatment of COPD for 1 year. Respirology 2006; 11: 603-10. [ Links ]

    202. McKay SE, Howie CA, Thomson AH, et al. Value of theophylline treatment in patients handicapped by chronic obstructive lung disease. Thorax 1993; 48: 227-32. [ Links ]

    203. Ford PA, Durham AL, Russell REK, et al. Treatment effects of low-dose theophylline combined with an inhaled corticosteroid in COPD. Chest 2010 137: 1338-44. [ Links ]

    204. To Y, Ito K, Kizawa Y, et al. Targeting phosphoinositide- 3-kinase-d with theophylline reverses corticosteroid insensitivity in COPD. Am J Respir Crit Care Med 2010; 182: 897-904. [ Links ]

    205. Zhou Y, Wang X, Zeng X, et al. Positive benefits of theophylline in a randomized, double-blind, parallel-group, placebo-controlled study of low-dose, slow-release theophylline in the treatment of COPD for 1 year. Respirology 2006; 11: 603-10. [ Links ]

    206. Man WD, Mustfa N, Nikoletou D, Kaul S. In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. An 85-day multicenter trial. COMBIVENT Inhalation Aerosol Study Group. Chest 1994; 105: 1411-9. [ Links ]

    207. Ikeda A, Nishimura K, Koyama H, Izumi T. Bronchodilating effects of combined therapy with clinical dosages of ipratropium bromide and salbutamol for stable COPD: comparison with ipratropium bromide alone. Chest 1995; 107: 401-5. [ Links ]

    208. COMBIVENT Inhalation Solution Study Group. Routine nebulized ipratropium and albuterol together are better than either alone in COPD. Chest 1997; 112: 1514-21. [ Links ]

    209. Gross N, Tashkin D, Miller R, Oren J, Coleman W, Linberg S. Inhalation by nebulization of albuterol-ipratropium combination is superior to either agent alone in the treatment of chronic obstructive pulmonary disease. Respiration 1998: 65: 354-62. [ Links ]

    210. van Noord J, Aumann J, Janssens E, et al. Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD. Chest 2006; 129: 509-17. [ Links ]

    211. van Noord JA, Aumann JL, Janssens E, et al. Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. Eur Respir J 2005; 26: 214-22. [ Links ]

    212. Tashkin DP, Cooper CB. The role of long-acting bronchodilators in the management of stable COPD. Chest 2004; 125: 249-59. [ Links ]

    213. Cazzola M, Centanni S, Santus P, et al. The functional impact of adding salmeterol and tiotropium in patients with stable COPD. Respir Med 2004; 98: 1214-21. [ Links ]

    214. Rossi A, Kristufek P, Levine BE, et al. Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD. Chest 2002; 21: 1058-69. [ Links ]

    215. Cazzola M, Gabriella Matera M. The additive effect of theophylline on a combination of formoterol and tiotropium in stable COPD: a pilot study. Respir Med 2007; 101: 957-62. [ Links ]

    216. Zuwallack RL, Mahler DA, Reilly D, et al. Salmeterol plus theophylline combination therapy in the treatment of COPD. Chest 2001; 119: 1661-70. [ Links ]

    217. Keatings J, Jatakanon A, Worsdell YM, Barnes PJ. Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD. Am J Respir Crit Care Med 1997; 155: 542-8. [ Links ]

    218. Culpitt S., Maziak W, Loukidis S, et al. Effect of high dose inhaled steroid on cells, cytokines, and proteases in induced sputum in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 160: 1635-9. [ Links ]

    219. Hattotuwa K, Gizycki MJ, Ansari TW, et al. The effects of inhaled fluticasone on airway inflammation in chronic obstructive pulmonary disease: a double-blind, placebo-controlled biopsy study. Am J Respir Crit Care Med 2002; 165: 1592-6. [ Links ]

    220. Gizycki MJ, Hattotuwa HL, Barnes N, Jeffery PK. Effects of fluticasone propionate on inflammatory cells in COPD: an ultrastructural examination of endobronchial biopsy tissue. Thorax 2002; 57: 799-803. [ Links ]

    221. Kiri VA, Pride NB, Soriano JB, Vestbo J. Inhaled corticosteroids in chronic obstructive pulmonary disease: results from two observational designs free of immortal time bias. Am J Respir Crit Care Med 2005; 172: 460-4. [ Links ]

    222. Pauwels RA, Lofdahl CG, Laitinen LA, et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on COPD. N Engl J Med 1999; 340: 1948-53. [ Links ]

    223. Burge PS, Calverley PM, Jones PW, et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000; 320: 1297-303. [ Links ]

    224. Paggiaro PL, Dahle R, Bakran I, et al. Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. Lancet 1998; 351: 773-80. [ Links ]

    225. Alsaeedi J, Sin DD, Finlay A, McAlister F. The effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review of randomized placebo-controlled trials. Am J Med 2002; 113: 59-65. [ Links ]

    226. Szafranski W, Cukier A, Ramirez A, et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 2003; 21: 74-81. [ Links ]

    227. Barnes NC, Yu-Sheng Qiu, Pavord ID, et al. Antiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease. Am J Respir Crit Care Med 2006; 173: 736-43. [ Links ]

    228. Hanania N A, Darken P, Horstman D, et al. The efficacy and safety of fluticasone propionate (250 g)/salmeterol (50 g) combined in the diskus inhaler for the treatment of COPD. Chest 2003; 124: 834-43. [ Links ]

    229. Bourbeau J, Christodoulopoulos P, Maltais F, et al. Effect of salmeterol/fluticasone propionate on airway inflammation in COPD: a randomised controlled trial. Thorax 2007; 62: 938-43. [ Links ]

    230. Nannini L, Cates CJ, Lasserson TJ, Poole P. Combined corticosteroid and long-acting beta-agonist in one inhaler versus placebo for chronic obstructive pulmonary disease (Cochrane Review). The Cochrane Library, Issue 3, 2004. [ Links ]

    231. Kardos P, Wencker M, Glaab T, Vogelmeier C. Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 175: 144-9. [ Links ]

    232. Aggarwal R, Aggarwal ANS, Gupta D, Jindal SK. Inhaled corticosteroids vs placebo for preventing COPD exacerbations: a systematic review and meta-regression of randomized controlled trials. Chest 2010; 137: 318-25. [ Links ]

    233. Sin DD, Wu L, Anderson JA, et al. Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease. Thorax 2005; 60: 992-7. [ Links ]

    234. Williams AJ, Baghat MS, Stableforth DE, et al. Dysphonia caused by inhaled steroids: recognition of a characteristic laryngeal abnormality. Thorax 1983; 38: 813-21. [ Links ]

    235. Toogood JH, Jennings B, Baskerville J, et al. Dosing regimen of budesonide and occurrence of oropharyngeal complications. Eur J Respir Dis 1984; 65: 35-44. [ Links ]

    236. Calverley PM, Boonsawat W, Cseke Z, et al. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J 2003; 22: 912-9. [ Links ]

    237. Wouters EF, Postma DS, Fokkens B, et al. Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial. Thorax 2005; 60: 480-7. [ Links ]

    238. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356: 775-89. [ Links ]

    239. Wilt TJ, Niewoehner D, MacDonald R, Kane RL. Management of stable chronic obstructive pulmonary disease: a systematic review for a clinical practice guideline. Ann Inter Med 2007; 147: 639-53. [ Links ]

    240. Aaron SD, Vandemheen KL, Fergusson D et al. Tiotropium in combination with placebo, salmeterol or fluticasone- salmeterol for treatment of chronic obstructive pulmoanry disease: a randomized trial. Ann Intern Med 2007; 146: 545-55. [ Links ]

    241. Welte T, Miravitlles M, Hernandez P, et al. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009; 180: 741-50. [ Links ]

    242. Welte T. Optimising treatment for COPD - new strategies for combination therapy. Int J Clin Pract 2009; 63: 1136-49. [ Links ]

    243. Qaseem A, Wilt T, Weinberger S, et al. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann Int Med 2011; 155: 179-91. [ Links ]

    244. Nichol KL., Margolis KL., Wuorenma J., Von Sternberg T. The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. N Engl J Med 1994; 331: 778-84. [ Links ]

    245. Wongsurakiat P, Lertakyamanee J, Maranetra KN, et al. Economic evaluation of influenza vaccination in Thai chronic obstructive pulmonary disease patients. J Med Assoc Thai 2003; 86: 497-508. [ Links ]

    246. Poole PJ, Chacko E, Wood-Baker RWB, Cates CJ. Influenza vaccine for patients with chronic obstructive pulmonary disease.(Cochrane Review). The Cochrane Library.Oxford: Update Software 2003; Issue 3. [ Links ]

    247. Woodhead M, Blasi F, Ewig S, et al. Guidelines for the management of adult lower respiratory tract infections. Eur Respir J 2005; 26: 1138-80. [ Links ]

    248. Jackson LA, Neuzil KM, Yu O, et al. Effectiveness of pneumococcal polysaccharide vaccine in older adults. N Eng J Med 2003; 348: 1747-55. [ Links ]

    249. Centers for Disease Control and Prevention. Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23). MMWR 2010; 59: 1102-6. [ Links ]

    250. Alfageme I, Vazquez R, Reyes N, et al. Clinical efficacy of anti-pneumococcal vaccination in patients with COPD. Thorax 2006; 61: 189-95. [ Links ]

    251. National Institute for Clinical Excellence. Guidance on the use of zanamivir, amantadine and oseltamivir for the treatment of influenza. London: National Institute for Clinical Excellence. NICE technology appraisal guidance- No.58. 2003. [ Links ]

    252. Dirksen A, Dijkman JH, Madsen F, et al. A randomized clinical trial of alpha1-antitrypsin augmentation therapy. Am J Respir Crit Care Med 1999; 160: 1468-72. [ Links ]

    253. The Alpha 1-Antitrypsin Deficiency Registry Study Group. Survival and FEV1 decline in individuals with severe deficiency of alpha 1-an titrypsin. Am J Respir Crit Care Med 1998; 158: 49-59. [ Links ]

    254. Chapman KR, Stockley RA, Dawkins C, et al. Augmentation therapy for alpha 1 antitrypsin deficiency: a meta-analysis. COPD 2009; 6: 177-84. [ Links ]

    255. Tonelli AR, Rouhani F, Pam NL, et al. Alpha-1-antitrypsin augmentation therapy in deficient individuals enrolled in the Alpha1 Foundation DNA and Tissue Bank. International Journal of COPD 2009; 4: 443-52. [ Links ]

    256. Dawkins PA, Dawkins CL, Wood AM, et al. Rate of progression of lung function impairment in a1-antitrypsin deficiency. Eur Respir J 2009; 33: 1335-41. [ Links ]

    257. Soriano JB, Miravitlles M. Your racing horses will help you to quit: a lesson for COPD and a1-antitrypsin deficiency research. Eur Resp J 2009; 33: 1244-6. [ Links ]

    258. Crosbie PA, Woodhead MA. Long term macrolide theraphy in chronic inflammatory airway diseases. Eur Respir J 2009; 33: 171-81. [ Links ]

    259. Wilkinson TM, Seemungal TA, Sapsford R, et al. Effect of Long-term Erythromycin in COPD Trial (ELECT): exacerbations and inflammation. Thorax 2007; 62(Suppl. 3): A15. [ Links ]

    260. Seemungal TAR, Wilkinson T, Hurst JR, et al. Long term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med 2008; 178: 1139-47. [ Links ]

    261. Guyatt GH, Towsend M, Kazim F, Newhouse MT. A controlled trial of ambroxol in chronic bronchitis. Chest 1987; 92: 618-29. [ Links ]

    262. Petty TL. The National Mucolytic Study: results of a randomized double blind placebo controlled study of iodinated glycerol in chronic obstructive bronchitis. Chest 1990; 97: 75-83. [ Links ]

    263. Poole PJ, Black PN. Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease. (Cochrane Review). The Cochrane Library.Oxford: Update Software 2003;Issue 3. [ Links ]

    264. Decramer M, Janssens W. Mucoactive therapy in COPD. Eur Respir Rev 2010; 19: 134-40. [ Links ]

    265. Stey C, Steurer J, Bachmann S, et al. The effect of oral N-acetylcysteine in chronic bronchitis: A quantitative systematic review. Eur Respir J 2000; 16: 253-62. [ Links ]

    266. Decramer M, Rutten-van Mölken M, Dekhuijzen PN, et al. Effects of N-acetylcysteine on outcomes in COPD (Bronchus Trial): a randomized placebo-controlled trial. Lancet 2005; 365: 1552-60. [ Links ]

    267. Collet JP, Shapiro P, Ernst P, et al. Effects of an immunostimulating agent on acute exacerbations and hospitalizations in patients with COPD. Am J Respir Crit Care Med 1997; 156: 1719-24. [ Links ]

    268. Li J, Zheng JP, Yuan JP, et al. Protective effect of a bacterial extract against acute exacerbation in patients with chronic bronchitis accompanied by COPD. Chin Med J 2004; 117: 828-34. [ Links ]

    269. Anthonisen NR. OMV-8BV for COPD. Am J Respir Crit Care Med 1997; 156: 1713-4. [ Links ]

    270. Soler M, Mutterlein R, Cozma G. Double-blind study of OM-85 in patients with chronic bronchitis or mild chronic obstructive pulmonary disease. Respiration 2007; 74: 26-32. [ Links ]

    271. Irwin RS, Boulet LP, Cloutier MM, et al. Managing cough as a defense mechanism and as a symptom: a consensus panel report of the American College of Chest Physicians. Chest 1998; 114: 133S-181S. [ Links ]

    272. Jennings AL, Davies AN, Higgins JPT, Broadley K. Opioids for the palliation of breathlessness in terminal illness. Cochrane Database Syst Rev 2001;4: CD002066. [ Links ]

    273. Jennings AL, Davies AN, Higgins JP, et al. A systematic review of the use of opioids in the management of dyspnea. Thorax 2002; 57: 939-44. [ Links ]

    274. Eiser N, Denman WT, West C, Luce P. Oral diamorphine: lack of effect on dyspnea and exercise tolerance in the pink puffer syndrome. Eur Respir J 1191; 4: 926-31. [ Links ]

    275. Young IH, Daviskas E, Keena VA. Effect of low dose nebulised morphine on exercise endurance in patients with chronic lung disease. Thorax 1989; 44: 387-90. [ Links ]

    276. Woodcock AA, Gross ER, Gellert A, Shah S, Johnson M, Geddes DM. Effects of dydrocodeine, alcohol, and caffeine on breathlessness and exercise tolerance in patients with chronic obstructive lung disease and normal blood gases. N Engl J Med 1981; 305: 1611-6. [ Links ]

    277. Rice KL, Kronenber RS, Niewoehner DE. Effects of chronic administration of codeine and promethazine on breathlessness and exercise tolerance in patients with chronic airflow obstruction. Br J Dis Chest 1987; 81: 287-92. [ Links ]

    278. Poole PJ, Veale AG, Black PN. The effect of sustained-release morphine on breathlessness and quality of life in severe COPD. Am J Respir Crit Care Med 1998; 157: 1877-80. [ Links ]

    279. Dandona P, Dhindsa S, Ghamim H, Chaudhuri A. Angiotensin II and inflammation: the effect of angiotensin-converting enzyme inhibition snf sngiotensin II receptors blockade. J Hum Hypertens 2007; 2: 20-7. [ Links ]

    280. Andreas S, Hermann-Lingen C, Raupach T, et al. Angiotensin II blockers in obstructive pulmonary disease: a randomized controlled trial. Eur Resp J 2006; 27: 972-9. [ Links ]

    281. Komajda M, Follath F, Swedberg K, et al. The study group of diagnosis of the working group on heart failure of the European Society of Cardiology. A survey among the quality of care among patients with heart failure in Europe. Eur Heart J 2003; 24: 464-74. [ Links ]

    282. Salpeter SR, Ormiston TM, Salpeter EE, et al. Cardioselective beta-blockers for chronic obstructive pulmonary disease: a meta-analysis. Respir Med 2003; 97: 1094-101. [ Links ]

    283. Ashrafian H, Violaris AG. Beta-blocker therapy of cardiovascular diseases in patients with bronchial asthma or COPD: the pro viewpoint. Prim Care Respir J 2005; 14: 236-41. [ Links ]

    284. Van Gestel YR, Hoeks SE, Sin DD, et al. Impact of selective beta-blockers on mortality in patients with chronic obstructive pulmonary disease and atherosclerosis. Am J Resp Crit Care Med 2008; 178: 695-700. [ Links ]

    285. Rutten FH, Zuithoff N, Hak E, Grobee DE, Hoes AW. Beta blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease. Arch Intern Med 2010; 170: 880-7. [ Links ]

    286. Sin DD, Man SFP. A curious case of -blockers in chronic obstructive pulmonary disease. Arch Intern Med 2010; 170: 849-50. [ Links ]

    287. Janda S, Park K, Fitzgerald M, et al. Statins in COPD. A systematic review. Chest 2009; 136: 734-43. [ Links ]

    288. Calverley PMA, Rabe KF, Goehring UM, et al. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 2009; 374: 685-94. [ Links ]

    289. Fabbri LM, Calverley PMA, Izquierdo-Alonso JL, et al. Roflumilast in moderate-to severe chronic obstructive pulmonary disease treated with long acting bronchodilators: two randomised trials. Lancet 2009; 374: 695-703. [ Links ]

    290. Report of the Medical Research Council Working Party. Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Lancet 1981; 1: 681-6. [ Links ]

    291. Kvale PA, Cugell DW, Anthonisen NR, et al. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease. Ann Intern Med 1980; 93: 391-8. [ Links ]

    292. O'Donnell DE, Aaron S, Bourbeau J, et al. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease - 2007 update. Can Respir J 2007; 14 (Suppl. B): 5B-32B. [ Links ]

    293. Somfay A, Porszasz J, Lee SM, Casaburi R. Dose-response effect of oxygen on hypertension and exercise endurance in non hypoxaemic COPD patients. Eur Respir J 2001; 18: 77-84. [ Links ]

    294. Liker ES, Karnick A, Lerner L. Portable oxygen in chronic obstructive lung disease with hypoxemia and cor pulmonale. Chest 1975; 68: 236-41. [ Links ]

    295. Rooyackers JM, Dekhuijzen PN, Van Herwaarden CL, Folgering HT. Training with supplemental oxygen in patients with COPD and hypoxaemia at peak exercise. Eur Respir J 1997; 10: 1278-84. [ Links ]

    296. Ambrosino N, Strambi S. New strategies to improve exercise tolerance in chronic obstructive pulmonary disease. Eur Respir J 2004; 24: 313-22. [ Links ]

    297. Lacasse Y, Lecours R, Pelletier C, et al. Randomised trial of ambulatory oxygen-dependent COPD. Eur Respir J 2005; 25: 1032-8. [ Links ]

    298. Eaton T, Gonett JE, Young P, et al. Ambulatory oxygen improves quality of life of COPD patients: a randomized controlled study. Eur Respir J 2002; 20: 306-12. [ Links ]

    299. Tarpy SP, Celli BR. Long-term oxygen therapy. N Engl J Med 1995; 333: 710-4. [ Links ]

    300. Ram FSF, Wedzicha JA. Ambulatory oxygen for chronic obstructive pulmonary disease (Review). The Cochrane Library 2009 (Issue 4): 1-24. [ Links ]

    301. Plywaczewski R, Sliwinski P, Nowinski A, et al. Incidence of nocturnal desaturation while breathing oxygen in COPD patients undergoing long-term oxygen therapy. Chest 2000; 117: 679-83. [ Links ]

    302. Fletcher EC, Luckett RA, Goodnight-White S, et al. A double-blind trial of nocturnal supplemental oxygen for sleep desaturation in patients with chronic obstructive pulmonary disease and daytime PaO2 above 60 mm Hg. Am Rev Respir Dis 1992; 145: 1070-6. [ Links ]

    303. Chaouat A, Wetzenblum E, Kessler R, et al. A randomized trial of nocturnal oxygen therapy in chronic obstructive pulmonary disease patients. Eur Respir J 1999; 14: 997-9. [ Links ]

    304. Apte NM, Karnad DR. Altitude hypoxaemia and the arterial-to-alveolar oxygen ratio. Ann Intern Med 1990; 112: 547-8. [ Links ]

    305. Gale GE, Torre-Bueno JR, Moon RE, et al. Ventilation-perfusion inequality in normal humans during exercise at sea level and simulated altitude. J Appl Physiol 1985; 58: 978-88. [ Links ]

    306. West JB, Wagner PD. Predicted gas exchange on the summit of Mt. Everest. Respir Physiol 1980; 42: 1-16. [ Links ]

    307. Ward MP. High altitude medicine and physiology. Ed. Ward MP, Milledge JS, West JB.London: Arnold; 2000.434p. [ Links ]

    308. BTS Statement. Management passengers with respiratory disease planning air travel. British Thoracic recommendations. Thorax 2002; 57: 289-304. [ Links ]

    309. Cakel RK, Partridge MR. Assessing the rise of hypoxia in flight: the need for more rational guidelines. Eur Resp J 2000; 15: 128-30. [ Links ]

    310. García Rio F, Borderías Calu L, Casanova Macario C, et al. Normativa SEPAR. Patología respiratoria y vuelos en avión. Arch Bronconeumonol 2007; 43: 101-25. [ Links ]

    311. Martinez Fraga A., Sivori M., Alonso M, Saenz C. Situación de la oxigenoterapia en vuelos nacionales e internacionales en Argentina. Medicina (B Aires) 2008; 68: 433-6. [ Links ]

    312. Gong H. Jr. Air travel and oxygen therapy in cardiopulmonary patients. Chest 1992; 101: 1104-13. [ Links ]

    313. Muhm MJ. Predicted arterial oxygenation at commercial aircraft cabin altitudes. Aviat Space Environ Med 2004; 75: 905-12. [ Links ]

    314. Robson A, Hartung T, Innes J. Laboratory assessment of fitness to fly in patients with lung disease: a practical approach. Eur Respir J 2000; 16: 214-9. [ Links ]

    315. Cullen DL. Long term oxygen therapy adherence and COPD: What we don't know. Chron Respir Dis 2006; 3: 217-22. [ Links ]

    316. Górecka D, Gorzelak K, Sliwinski P, et al. Effect of long-term oxygen therapy on survival in patients with chronic obstructive pulmonary disease with moderate hypoxemia. Thorax 1997; 52: 674-9. [ Links ]

    317. Kolodziej MA, Jensen L, Rowe B, Sin D. Systematic review of noninvasive positive pressure ventilation in severe stable COPD. Eur Respir J 2007; 30: 293-306. [ Links ]

    318. Clini EM., Ambrosino N. Nonpharmacological treatment and relief of symptoms in COPD. Eur Respir J 2008; 32: 218-28. [ Links ]

    319. Petty TL, Stanford RE, Neff TA. Continuous oxygen therapy in chronic airway obstruction: observations on possible oxygen toxicity and survival. Ann Intern Med 1971; 75: 361-7. [ Links ]

    320. ATS/ERS. Statement on Pulmonary Rehabilitation. Am J Crit Care Med 2006; 173: 1390-413. [ Links ]

    321. Ringbaek TJ, Broendum E, Hemmingsen L, et al. Rehabilitation of patients with chronic obstructive pulmonary disease: exercise twice a week is not sufficient. Respir Med 2000; 94: 150-4. [ Links ]

    322. Troosters T, Casabury R, Gosselink R, Decramer M. Pulmonary Rehabilitation in Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 2005; 172: 19-38. [ Links ]

    323. Sivori M, Benzo R, Rhodius E, et al. Consenso Argentino de Rehabilitación Respiratoria. Medicina( B Aires) 2004; 64: 357-67. [ Links ]

    324. Bradley JM, Lasserson T, Elborn S, et al. A systematic review of randomized controlled trials examining the short-term benefit of ambulatory oxygen in COPD. Chest 2007; 131: 278-85. [ Links ]

    325. Ries A, Bauldoff G, Carlin B, et al. Pulmonary Rehabilitation: Joint ACCP/AACVPR Evidence-Based Clinical Practice Guidelines. Chest 2007; 131: 4S-42S. [ Links ]

    326. Bradley JM, O´Neill B. Short-term ambulatory oxygen for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 005;19: CD004356. [ Links ]

    327. Clini E, Sturani C, Rossi A et al. The Italian multicentre study on non invasive ventilation in chronic obstructive pulmonary disease patients. Eur Respir J 2002; 20: 529-38. [ Links ]

    328. Consensus conference report: Clinical indication for non invasive positive pressure ventilation in chronic respiratory failure due to restrictive lung disease, COPD, and nocturnal hypoventilation. Chest 1999; 116; 521-34. [ Links ]

    329. Bourbeau J. The role of collaborative self-management in pulmonary rehabilitation. Semin Respir Crit Care Med 2009; 30: 700-7. [ Links ]

    330. Hernandez P, Balter M, Bourbeau J, Hodder R. Living with chronic obstructive pulmonary disease: a survey of patients' knowledge and attitudes. Respir Med 2009; 103: 1004-12. [ Links ]

    331. Sedeno MF, Nault D, Hamd DH, Bourbeau J. A self-management education program including an action plan for acute COPD exacerbations. COPD 2009; 6: 352-8. [ Links ]

    332. Adams SG, Smith PK, Allan PF, Anzueto A, Pugh JA, Cornell JE. Systematic review of the chronic care model in chronic obstructive pulmonary disease prevention and management. Arch Intern Med 2007; 167: 551-61. [ Links ]

    333. Whittaker JS, Ryan CF, Buckley PA, Road JD. The effect of re-feeding on peripheral and respiratory muscle function in malnourished chronic obstructive pulmonary disease patients. Am Rev Respir Dis 1990; 142: 283-8. [ Links ]

    334. Rogers RM, Donahoe M, Constantino J. Physiologic effects of oral supplementation feeding in malnourished patients with chronic obstructive pulmonary disease. A randomized control study. Am Rev Respir Dis 1992; 146: 1511-7. [ Links ]

    335. Steiner MC, BartonRL, Singh SK, Morgan MD. Nutritional enhancement of exercise performance in chronic obstructive pulmonary disease patients: a randomized trial. Thorax 2003; 58: 745-51. [ Links ]

    336. Rogers RM, Donahoe M, Constantino J. Physiologic effects of oral supplementation feeding in malnourished patiens with chronic obstructive pulmonary disease. A randomized control study. Am Rev Respir Dis 1992; 146: 1511-7. [ Links ]

    337. Martinez F, Chang A. Surgical therapy for chronic obstructive pulmonary disease. Semin Respir Crit Care Med 2005; 26: 167-91. [ Links ]

    338. Snider GL. Reduction pneumoplasty for giant bullous emphysema. Implications for surgical treatment of nonbullous emphysema. Chest 1996; 109: 540-8. [ Links ]

    339. Naunheim KS, Wood DE, Mohenifar Z, et al. Long-term follow-up of patients receiving lung-volume-reduction surgery versus medical therapy for severe emphysema by the National Emphysema Treatment Trial Research Group. Ann Thorac Surg 2006; 82: 431- 43. [ Links ]

    340. Orens JB, Estenne M, Arcasoy S, et al. International guidelines for the selection of lung transplant candidates: 2006 Update-a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2006; 25: 745-55. [ Links ]

    341. Varela A, Álvarez Kindelan A, Román A, et al. Grupo de trabajo de la SEPAR. Normativa SEPAR. Trasplante pulmonar. Arch Bronconeumol 2001; 37:307-15. [ Links ]

    342. Venuta F, Rendina EA, De Giacomo T, et al. Bronchoscopic procedures for emphysema treatment. Eur J Cardiothorac Surg 2006; 29: 281-7. [ Links ]

    343. Sciurba FC, Ernst A, Herth FJ, et al. A randomized study of endobronchial valves for advanced emphysema. N Engl J Med 2010; 363: 1233-44. [ Links ]

    344. Jones PW. Quality of life measurement for patients with diseases of the airways. Thorax 1991; 46: 676-82. [ Links ]

    345. Jones W, Harding G, Berry P, et al. COPD Development and first validation of the COPD Assessment Test. Eur Respir J 2009; 34: 648-54. [ Links ]

    346. Guell R, Casan P, Sangenis M, Morante F, Belda J, Guyatt GH. Quality of life in patients with chronic respiratory disease: the Spanish version of the chronic respiratory questionnaire (CRQ). Eur Respir J 1998; 11: 55-60. [ Links ]

    347. Jones PW, Quirk FH, Baveystock CM. The St George's Respiratory Questionnaire. Respir Med 1991; 85 Suppl B: 25-31. [ Links ]

    348. Lynn J, Goldstein NE. Advance care planning for fatal chronic illness: avoiding common place errors and unwarranted suffering. Ann Intern Med 2003; 138: 812-8. [ Links ]

    349. Código de Ética para el equipo de Salud de la Asociación Médica Argentina. Buenos Aires, Argentina, 2002. [ Links ]

    350. Guía de Cuidados Paliativos. SECPAL (Sociedad Española de Cuidados Paliativos) http://www.secpal.com/guiacp/guiacp.pdf. Consultado 12 de diciembre de 2009. [ Links ]

    351. Legislación Nacional. Dictámenes de mayoría y minoría sobre el Proyecto de Ley de Régimen de los derechos de los enfermos terminales. Comisiones de Acción Social y Salud Pública, de Legislación General y de Legislación Penal. Sala de las Comisiones, 9 de octubre de 1996. En: http://www.muerte.bioetica.org/legis/leyproy.htm; consultado el 12/12/2009. [ Links ]

    352. Tripodoro V. Cuidados paliativos: El final de la vida en pacientes respiratorios crónicos. Rev Arg Med Respir 2004; 4:48-53 [ Links ]

    353. Alvarez-Sala JL, Cimas E, Masa JF, et al. Grupo de Trabajo de la Sociedad Española de Neumología y Cirugía Torácica (SEPAR) y de la Sociedad Española de Medicina de Familia y Comunitaria (semFYC). Recomendaciones para la atención al paciente con enfermedad pulmonar obstructiva crónica. Arch Bronconeumol 2001; 37: 269-78. [ Links ]

    354. World Health Organization. International Classification of Impairments, Disabilities and Handicaps. Geneva: World Health Organization,1980. [ Links ]

    355. Guidelines for the evaluation of impairment/disability in patients with asthma. American Thoracic Society. Medical Section of the American Lung Association. Am Rev Respir Dis 1993; 147: 1056-61. [ Links ]

    356. American Medical Association. Guides to the evaluation of permanent impairment, 4th ed, Chicago: American Medical Association, 1993. [ Links ]

    357. Rodriguez Roisin R. Toward a consensus definition for COPD exacerbations. Chest 2000; 117: 398S-401S. [ Links ]

    358. Niewoehner DE, Lokhnygina Y, Rice K, et al. Risk indexes for exacerbations and hospitalizations due to COPD. Chest 2007; 131: 20-8. [ Links ]

    359. Bhowmik A, Seemungal TA, Sapsford RJ, Wedzicha JA. Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations. Thorax 2000; 55: 114-20. [ Links ]

    360. Crooks SW, Bayley DL, Hill SL, Stockley RA. Bronchial inflammation in acute bacterial exacerbations of chronic bronchitis: the role of leukotriene B4. Eur Respir J 2000; 15: 274-80. [ Links ]

    361. Seemungal TAR, Harper-Owen R, Bhowmik A, et al. Respiratory viruses, symptoms and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164: 1618-23. [ Links ]

    362. Hurst JR, Perera WR, Wilkinson TM. Systemic and upper and lower airway inflammation at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006; 173: 71-8. [ Links ]

    363. Drost EM, Skwarski KM, Sauleda J, et al. Oxidative stress and airway inflammation in severe exacerbations of COPD.Thorax 2005; 60: 293-300. [ Links ]

    364. Murphy TF, Brauer AL, Schiffmacher AT, et al. Persistent colonization by Haemophilus influenzae in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004; 170: 266-72. [ Links ]

    365. Spencer S, Jones PW for the GLOBE Study Group. Time course of recovery of health status following an infective exacerbation of chronic bronchitis. Thorax 2003; 58: 589-93. [ Links ]

    366. Currie GP, Wedzicha JA. Acute exacerbations. BMJ 2006; 333;87-9. [ Links ]

    367. Bradley SG, Wen QG, Don DS. Contemporary Management of Acute Exacerbations of COPD. Chest 2008; 133:756-66. [ Links ]

    368. Connors AF Jr, Dawson NV, Thomas C, et al. Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (Study to understand prognoses and preferences for outcomes and risks of treatments). Am J Respir Crit Care Med 1996; 154: 959-67. [ Links ]

    369. Gunen H, Hacievliyagil S, Kosar F, et al. Factors affecting survival of hospitalised patients with COPD. Eur Respir J 2005; 26: 234-41. [ Links ]

    370. Soler-Cataluña JJ, Martínez-García A, Román-Sánchez P, et al. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 2005; 60: 925-31. [ Links ]

    371. Celli B, Barnes P. Exacerbations of chronic obstructive pulmonary disease. Eur Respir J 2007; 29: 1224-38. [ Links ]

    372. Aaron SD, Vandemheen KL, Hebert P, et al. Outpatient oral prednisone after emergency treatment of chronic obstructive pulmonary disease. N Engl J Med 2003; 348: 2618-25. [ Links ]

    373. Bullard MJ, Liaw SJ, Tsai YH, et al. Early corticosteroid use in acute exacerbations of chronic airflow obstruction. Am J Emerg Med 1996; 14: 139-43. [ Links ]

    374. Davies L, Angus RM, Calverley PM. Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomized controlled trial. Lancet 1999; 354: 456-60. [ Links ]

    375. Maltais F, Ostinelli J, Bourbeau J, et al. Comparison of nebulized budesonide and oral prednisolone with placebo in the treatment of acute exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Am J Respir Crit Care Med 2002; 165: 698-703. [ Links ]

    376. Niewoehner DE, Erbland ML, Deupree RH, et al. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease: department of Veterans Affairs Cooperative Study Group. N Engl J Med 1999; 340: 1941-7. [ Links ]

    377. Thompson WH, Nielson CP, Carvalho P, et al. Controlled trial of oral prednisone in outpatients with acute COPD exacerbation. Am J Respir Crit Care Med 1996; 154: 407-12. [ Links ]

    378. Wilkinson TM, Donaldson GC, Hurst JR, et al. Early therapy improves outcomes of exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004; 169: 1298-303. [ Links ]

    379. Stockley RA, O´Brien C, Pye A, Hill SL. Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD. Chest 2000; 117: 1638-45. [ Links ]

    380. Nouira S, Marghli S, Belghith M, et al. Once daily oral ofloxacin in chronic obstructive pulmonary disease exacerbation requiring mechanical ventilation: a randomised placebocontrolled trial. Lancet 2001; 358: 2020-25. [ Links ]

    381. Ram FS, Rodriguez-Roisin R, Granados-Navarrete A, et al. Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2006; CD004403. [ Links ]

    382. Torres A. COPD guidelines in relation to infections: a critical analysis. Breathe 2009; 5: 317-21. [ Links ]

    383. Soler N, Torres A, Ewig S, et al. Bronchial microbial patterns in severe exacerbations of chronic obstructive pulmonary disease (COPD) requiring mechanical ventilation. Am J Respir Crit Care Med 1998; 157: 1498-505. [ Links ]

    384. Miratvilles M, Espinosa C, Fernández Laso E, et al. Relationship between bacterial flora in sputum and exacerbations in patients with acute exacerbations of COPD. Chest 1999; 116: 40-6. [ Links ]

    385. García Vidal C, Almagro P, Romani V, et al. Pseudomonas aeruginosa in patients hospitalized for COPD exacerbation: a prospective study. Eur Respir J 2009; 34: 1072-8 . [ Links ]

    386. Soler N, Agustí C, Angrill J, et al. Bronchoscopic validation of the significance of sputum purulence in severe exacerbations of chronic obstructive pulmonary disease. Thorax 2007; 62: 29-35. [ Links ]

    387. El Moussaoui R, Roede BM, Speelman P, et al. Short-course antibiotic treatment in acute exacerbations of chronic bronchitis and COPD: a meta-analysis of double-blind studies. Thorax 2008; 63: 415-22. [ Links ]

    388. BTS guidelines. Non-invasive ventilation in acute respiratory failure. Thorax 2002; 57: 192-211. [ Links ]

    389. Brochard L, Mancebo J, Elliott MW. Noninvasive ventilation for acute respiratory failure. Eur Respir J 2002; 19: 712-21. [ Links ]

    390. Diez AR, Abbona H, Ferrero G, et al. Argentine consensus of non-invasive ventilation. Medicina (B Aires) 2005; 65: 437-57. [ Links ]

    391. Confalonieri M, Garuti G, Cattaruzza MS, et al. Italian noninvasive positive pressure ventilation (NPPV) study group. A chart of failure risk for noninvasive ventilation in patients with COPD exacerbation. Eur Respir J 2005; 25: 348-55. [ Links ]

    392. Bott J, Carroll MP, Conway JH, et al. Randomised controlled trial of nasal ventilation in acute ventilatory failure due to chronic obstructive airways disease. Lancet 1993; 341: 1555-7. [ Links ]

    393. Plant PK, Owen JL, Elliott MW. Non-invasive ventilation in acute exacerbations of chronic obstructive pulmonary disease: long term survival and predictors of in-hospital outcome. Thorax 2001; 56: 708-12. [ Links ]

    394. Ram FS, Picot J, Lightowler J, Wedzicha JA. Non-invasive positive pressure ventilation for treatment of respiratory failure due to exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2004; CD004104. [ Links ]

    395. Garpestad E, Brennan J, Hill NS. Noninvasive ventilation for critical care. Chest 2007; 132: 711-20. [ Links ]

    396. American Thoracic Society, European Respiratory Society, European Society of Intensive Care Medicine and Société de Réanimation de Langue Française. International Consensus Conferences in Intensive Care Medicine: Non invasive positive pressure ventilation in acute respiratory failure. Am J Respir Crit Care Med 2001; 163: 283-91. [ Links ]

    397. Brochard L, Isabey D, Piquet J, et al. Reversal of acute exacerbations of chronic obstructive lung disease by inspiratory assistance with a face mask. N Engl J Med 1990; 323: 1523-30. [ Links ]

    398. MacIntyre NR, Cook DJ, Ely EW Jr, et al. Evidence-based guidelines for weaning and discontinuing ventilatory support: a collective task force facilitated by the American College of Chest Physicians; the American Association for Respiratory Care; and the American College of Critical Care Medicine. Chest 2001; 120: 375S-95S. [ Links ]

    399. MacIntyre N, Huang YC. Acute exacerbations and respiratory failure in chronic obstructive pulmonary disease. Proc Am Thor Soc 2008; 5: 530-5. [ Links ]

    400. Sociedad Argentina de Terapia Intensiva. Enfermedad pulmonar obstructiva crónica. Capítulo 14. Terapia Intensiva 4ta. Edición, Buenos Aires: Editorial Médica Panamericana, 2007. [ Links ]

    401. Boles JM, Bion J, Connors A, et al. Weaning from mechanical ventilation. Eur Respir J 2007; 29: 1033-56. [ Links ]

    402. Burns KE, Adhikari NK, Meade MO. A meta-analysis of noninvasive weaning to facilitate liberation from mechanical ventilation. Can J Anaesth 2006; 53: 305-15. [ Links ]